Daratumumab and Hyaluronidase-fihj
This page contains brief information about daratumumab and hyaluronidase-fihj and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.
Use in Cancer
Daratumumab and hyaluronidase-fihj is approved to be used alone or with other drugs to treat:
- Multiple myeloma. It is used:
- In adults with newly diagnosed disease. It is used with bortezomib, melphalan, and prednisone or with lenalidomide and dexamethasone in patients who cannot receive an autologous stem cell transplant.
- In adults with relapsed or refractory disease. It is used:
- With dexamethasone and either lenalidomide or bortezomib in patients who have received at least one therapy.
- Alone in patients who have already received at least three types of therapy that included a proteasome inhibitor and an immunomodulating agent or whose disease is refractory to both a proteasome inhibitor and an immunomodulatory agent.
Daratumumab and hyaluronidase-fihj is a form of daratumumab that is given as a subcutaneous injection. This form can be given more quickly than daratumumab, which is given as an infusion. This shortens the amount of time it takes to receive each treatment. For more information about daratumumab that may apply to daratumumab and hyaluronidase-fihj, see the Drug Information Summary for Daratumumab.
Daratumumab and hyaluronidase-fihj is also being studied in the treatment of other types of cancer.
More About Daratumumab and Hyaluronidase-fihj
Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.
Research Results and Related Resources
Clinical Trials Accepting Patients
Find Clinical Trials for Daratumumab And Hyaluronidase-fihj - Check for trials from NCI's list of cancer clinical trials now accepting patients.